Insmed Incorporated stock rating and score history
All changes in ratings, performance and outlook tracked over time.
Insmed Incorporated stock price, chart patterns and momentum
Recent price movements, trend behaviour and momentum signals based on real-time market data.
What does Insmed Incorporated do? Business model and key facts
Get the full picture of Insmed Incorporated: what it builds, where it operates, and how it makes money.
Sector: Healthcare
Industry: Biotechnology
Employees (FY): 1271
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.
Stocks related to Insmed Incorporated
Selected based on industry alignment and relative market positioning.
Events and news impacting Insmed Incorporated stock
Earnings, coporate decisions and industry developments that can affect the share price.
Insmed Incorporated fundamentals and technical analysis
Financial fundamentals and technicals signals combined to access stability, momentum and market direction.
